ULTI Ultimovacs

Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation

Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation

Oslo, October 31, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its third quarter 2024 results, on Wednesday, November 6, 2024.

The presentation can be followed as a live webcast accessed through a link on at 14:00 CET on Wednesday, November 6, 2024. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through the webcast.

The report and presentation will be available on the company website from 07:00 CET the same day.

For further information, please see or contact:

Carlos de Sousa, CEO

Email:

Phone:

Hans Vassgård Eid, CFO

Email:

Phone:



 

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act



EN
31/10/2024

Underlying

ULTIUltimovacs

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultimovacs

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
4h / 27m 4h / 27m 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provid...

Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update Oslo, November 6, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its third quarter 2024 results today. Conference call and webcast scheduled for November 6, 2024, at 14:00 (CET). Link to webcast . Third Quarter 2024 Business Update Highlights Ultimovacs implemented cash preservation initiatives during the second quarter of 2024. During the third quarter of 2024, additional cash preservation op...

5h / 39m 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA: Invitation to third quarter 2024 results webcast prese...

Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation Oslo, October 31, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its third quarter 2024 results, on Wednesday, November 6, 2024. The presentation can be followed as a live webcast accessed through a link on at 14:00 CET on Wednesday, November 6, 2024. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation throug...

October 31, 2024 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs Announces Publication of Phase II FOCUS Trial Results on me...

Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv Oslo, October 25, 2024: (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the results from Phase II FOCUS trial () have been on the preprint platform medRxiv. As previously , topline data readout demonstrated that adding UV1 to the standard of care pembrolizumab did not lead to clinical benefits in progression free survival or overall survival in the late-stage head and neck squamous cell carcinoma (HNSCC) patients recruited in th...

October 25, 2024 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Tr...

Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer Oslo, September 11, 2024: (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company has agreed with the investigators conducting the LUNGVAC trial () to discontinue patient recruitment. LUNGVAC is an investigator-initiated, randomized Phase II trial designed to assess the impact of UV1 in combination with the checkpoint inhibitor cemiplimab o...

September 11, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch